Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 41

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 41
---
 entered
into the 2025 Warrant Agreements with certain Holders of our outstanding Series E Warrants, Series H Warrants, Series J Warrants, and
Series K Warrants issued in prior transactions, pursuant to which the Holders agreed to exercise certain of such warrants in exchange
for a reduction in exercise price of each warrant to $0.31 per share. An aggregate of 200,433 warrants were exercised for aggregate gross
proceeds of approximately $62,000, before estimated offering expenses. We did not issue new warrants to replace the warrants that were
exercised.

eRapa Granted Orphan Drug Designation in Europe

On May 12, 2025, we announced
that the European Commission had granted Orphan Drug Designation for eRapa in FAP. Orphan Drug Designation in the European Union is granted
by the European Commission based on a positive opinion issued by the EMA Committee for Orphan Medicinal Products. It is intended to encourage
the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases. If approved
for marketing, this designation will provide 10 years of marketing exclusivity and also provide special incentives for sponsors, including
eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees.

For more information on recent
developments with respect to eRapa, see “—Company Overview.”

Contingent Liability

As previously disclosed in
the Notes to the Consolidated Unaudited Interim Financial Information for the six-month period ended June 30, 2025, we were involved in
a dispute with a former advisor regarding fees. The dispute was resolved through a settlement, the terms of which included a payment made
to the former advisor on September 29, 2025.

Our Strategy

In early 2023, we decided
to re-position the Company as therapeutics (as opposed to drug delivery) company and we began looking for additional assets to complement
our MTX110 programs. The delivery of proof-of-concept clinical data is the primary focus of our business model going forward.

Our proprietary drug delivery
technologies are no longer a key priority for the Company.

Development

Our intention is to build
a balanced portfolio of clinical-stage development assets, ideally with a focus on rare / orphan indications. eRapa was in-licensed in
April 2024 and is being developed for FAP and NMIBC. We expect to begin enrolling a multi-center registrational